Antisoma PLC Presents Positive Data On AS1409, Expects Trials To Start Mid-2006
Cancer drug developer Antisoma plc (LSE:ASM) announces the presentation yesterday of new preclinical data on AS1409. These show the success of tumour-targeting by the drug and how this translates into potent effects on the growth of different tumours. Antisoma has made rapid progress in developing AS1409 and, with formal toxicology studies underway, now expects to start clinical trials in mid-2006.